← Back to Search

CAR T-cell Therapy

T Cell Immunotherapy for Non-Hodgkin's Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Xcyte Therapies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Received at least one prior course of systemic therapy for NHL and no more than four prior courses of therapy
Stage III or IV disease at any time in the past
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing a new T cell immunotherapy for patients with indolent non-Hodgkin's lymphoma who have relapsed or are refractory to other treatments. The primary endpoint is efficacy, and secondary endpoints are safety and changes in various blood cell counts and immune responses.

Who is the study for?
Adults with indolent non-Hodgkin's Lymphoma who've had 1-4 prior treatments can join this trial. They must have measurable disease, be in fair health (ECOG 0-2), and meet specific blood count criteria. Those with a history of other cancers or certain lymphomas, recent immunotherapy, or active infections are excluded.Check my eligibility
What is being tested?
The study is testing Xcellerated T CellsTM therapy for patients whose NHL has returned or hasn't responded to treatment. It aims to boost the immune system's ability to fight cancer by using the patient's own modified T cells.See study design
What are the potential side effects?
Potential side effects may include reactions related to the immune system being overly activated, such as fever and fatigue, as well as possible infusion-related reactions. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had 1-4 treatments for non-Hodgkin lymphoma.
Select...
My condition was diagnosed as stage III or IV at some point.
Select...
My condition worsened or didn't improve after my last treatment.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My liver and kidneys are working well.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Xcyte TherapiesLead Sponsor
3 Previous Clinical Trials
83 Total Patients Enrolled
Mark W. Frohlich, MDStudy ChairXcyte Therapies

Media Library

Xcellerated T CellsTM (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00081783 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups:
Non-Hodgkin's Lymphoma Clinical Trial 2023: Xcellerated T CellsTM Highlights & Side Effects. Trial Name: NCT00081783 — Phase 2
Xcellerated T CellsTM (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00081783 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What precautions have been taken to ensure the safety of those receiving this therapy?

"This experimental treatment has not yet been proven to be efficacious in clinical trials, thus receiving a safety score of 2."

Answered by AI

What criteria should a potential participant meet to qualify for this research trial?

"This trial is recruiting 40 participants with non-Hodgkin's Lymphoma, who must meet the following criteria: be of age 18 or above; have had at least one prior course of systemic therapy but not more than four courses (single agent rituximab excluded); belong to any subtype according to the REAL Classification except mantle cell lymphoma and small lymphocytic lymphoma which are limited respectively to 8 and 16 patients; have Stage III or IV disease at some point in their medical history; present as either refractory or relapsed after most recent treatment, depending on time to disease progression; possess an EC"

Answered by AI

In which geographical areas can participants access this trial?

"18 sites are participating in this medical trial. These locations include the Cancer Institute of New jersey in New Brunswick, Oregon Health Sciences University in Portland, and Rocky Mountain Cancer Centers located in Denver to name a few."

Answered by AI

Is this experiment actively seeking participants?

"According to the clinicaltrials.gov database, this trial is not actively recruiting participants. The first posting was on March 1st 2004 and it has been since edited the last time being June 23rd 2005. Though inactive at present, there are an abundance of alternate trials currently searching for patients - 1778 in total!"

Answered by AI

Is there an age cutoff for inclusion in this analysis?

"This medical investigation is seeking participants that are 18 years old or older and younger than 80."

Answered by AI
~2 spots leftby Mar 2025